Deerfield
About Deerfield

Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment, and philanthropy—all toward the end goal of cures for disease, improved quality of life, and reduced cost of care.

Read More
---
Investment

Supporting companies across the healthcare ecosystem with flexible funding models…

Read More
---
Information

Delivering market research to the Deerfield team, its portfolio companies and other partners.

Read More ---
Philanthropy

A New York City-based not-for-profit devoted to advancing innovative health care initiatives.

Read More
---
Research Collaborations

Deerfield partners with leading academic research centers, providing critical funding and expertise to further sustain and accelerate the commercialization of discoveries toward meaningful societal impact by advancing cures for disease.

Read More
---
Strategic Partners

As a strategic partner, Deerfield offers capital, scientific expertise, business operating support, and unique access to innovation.

---
Deerfield Foundation

The Deerfield Foundation is a New York City-based not-for-profit organization whose mission is to improve health, accelerate innovation and promote human equity.

Read More Meet the Foundation Team
---
Cure Campus

Cure is a 12-story innovations campus in New York City that intends to bring together innovators from academia, government, industry, and the not-for-profit sectors to advance human health and accelerate the fight against disease.

Read More Meet the Cure Team Join the Cure Email List
Cure Programming

Cure has a series of expert lectures intended to advance thought in healthcare, management, innovation, policy, and other relevant subjects. This fosters growth and education for those at Cure and its guests.

Cure Symposium Calendar

Tian Yang, Ph.D.

Tian Yang, Ph.D., is a Vice President, Preclinical Development, Deerfield Discovery and Development, and joined the Firm in 2022. Prior to Deerfield, Dr. Yang spent ten years at the Global Alliance for TB Drug Development with responsibility for toxicology, as well as drug metabolism and pharmacokinetics (DMPK). Before TB Alliance, he worked as Head of Enzymology and Drug Metabolism at Hoffmann-La Roche, and held various other roles at Bristol Myers Squibb and Dupont Pharmaceutical. He began his career at the National Cancer Institute, researching carcinogen-activating P450s. Dr. Yang holds a B.S. in Pharmacy from Lanzhou University, and a Ph.D. in Pharmacology and Toxicology from Peking Union Medical College. Dr. Yang is a Diplomate of the America Board of Toxicology (DABT).